Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

Eitemau Tebyg

• Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
  gan: Abernethy, Amy P., et al.
  Cyhoeddwyd: (2017)
• Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
  gan: Cai, Weijing, et al.
  Cyhoeddwyd: (2015)
• Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
  gan: Lou, Na-Na, et al.
  Cyhoeddwyd: (2016)
• Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
  gan: Marino, Federica Zito, et al.
  Cyhoeddwyd: (2015)
• Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target
  gan: Galetta, Domenico, et al.
  Cyhoeddwyd: (2016)